Cover Image
Read Now

CNS clinical trials suicidality and data collection : workshop summary

"The Food and Drug Administration (FDA) now requires that all clinical trials for drugs that affect the central nervous system--including psychiatric drugs--are assessed for whether that drug might cause suicidal ideation or behavior. The Institute of Medicine's (IOM) Forum on Neuroscience...

Full description

Bibliographic Details
Main Author: Hanson, Sarah L.
Corporate Authors: Institute of Medicine (U.S.) Forum on Neuroscience and Nervous System Disorders, National Academies Press (U.S.)
Other Authors: Davis, Miriam, Altevogt, Bruce M.
Format: eBook
Language:English
Published: Washington, D.C. National Academies Press 2010, c2010
Subjects:
Suicide / Prevention & Control
United States
Clinical Trials As Topic
Mental Disorders
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
LEADER 02234nam a2200373 u 4500
001 EB000942742
003 EBX01000000000000000736332
005 00000000000000.0
007 tu|||||||||||||||||||||
008 150223 r ||| eng
020 |a 0309148839 
020 |a 9780309148832 
050 4 |a RC569 
100 1 |a Hanson, Sarah L. 
245 0 0 |a CNS clinical trials  |h Elektronische Ressource  |b suicidality and data collection : workshop summary  |c Sarah Hanson, Miriam Davis, and Bruce Altevogt, rapporteurs ; Forum on Neuroscience and Nervous System Disorders, Board on Health Sciences Policy, Institute of Medicine of the National Academies 
246 3 1 |a Central nervous system clinical trials 
260 |a Washington, D.C.  |b National Academies Press  |c 2010, c2010 
300 |a xii, 75 p.  |b ill.  |c 23 cm 
505 0 |a Includes bibliographical references (p. 43-49) 
505 0 |a Perspectives from the FDA, academia, and patients -- Data collection and optimization -- Data analysis -- Partnerships, opportunities, collaboration 
653 |a Suicide / prevention & control 
653 |a United States 
653 |a Clinical Trials as Topic 
653 |a Mental Disorders 
700 1 |a Davis, Miriam 
700 1 |a Altevogt, Bruce M. 
710 2 |a Institute of Medicine (U.S.)  |b Forum on Neuroscience and Nervous System Disorders 
710 2 |a National Academies Press (U.S.) 
041 0 7 |a eng  |2 ISO 639-2 
989 |b NCBI  |a National Center for Biotechnology Information 
856 4 0 |u https://www.ncbi.nlm.nih.gov/books/NBK52956  |3 Volltext  |n NLM Bookshelf Books  |3 Volltext 
856 4 0 |u http://www.nap.edu/catalog.php?record_id=12829  |3 Volltext  |n Provider site  |3 Volltext 
082 0 |a 610 
520 |a "The Food and Drug Administration (FDA) now requires that all clinical trials for drugs that affect the central nervous system--including psychiatric drugs--are assessed for whether that drug might cause suicidal ideation or behavior. The Institute of Medicine's (IOM) Forum on Neuroscience and Nervous System Disorders hosted a meeting on June 26, 2009, to discuss the FDA's new policy and how to analyze best whether suicidal thoughts predict actual suicidal behavior in the near future."--Publisher's description 

Similar Items